![]() A variety of medication classes have been examined in the treatment of PG with varying results. Study outcome and the mean dose of medication administered was documented in an effort to determine a preferred medication choice in this population. A systematic review of the 18 double-blind, placebo-controlled pharmacotherapy studies conducted for the treatment of pathological gambling was conducted. This review seeks to examine the history of medication treatments for PG. ![]() Although common and financially devastating to individuals and families, there currently exist no formally approved pharmacotherapeutic interventions for this disorder. ![]() Currently available treatments are associated with extremely high relapse rates.Pathological gambling (PG) is a relatively common and often disabling psychiatric condition characterized by intrusive urges to engage in deleterious gambling behaviour. Pathological gambling affects approximately one to two percent of the population. Additional research is needed to further refine the subtypes. ![]() Grant cautioned that while these results are exciting and a majority of people respond to these medications, there are still some for whom these medications do not work. "When we look at pathological gambling as an addiction and try to understand the sense of urges and inhibitions, we are able to target the treatment with medication more effectively." "By understanding these different subtypes, we are able to target the core biology of the illness with individualized treatment," said Jon Grant, MD, JD, MPH, Associate Professor of Psychiatry at the University of Minnesota and ACNP member. Researchers found that decreasing the function of COMT can increase one's ability to inhibit their desire to gamble. The second subtype, gamblers who have difficulty inhibiting their behaviors and react to the smallest desires, respond well to medications that act on a specific enzyme, catechol-O-methyl-transferase (COMT), which plays a major role in the function of the prefrontal cortex. People with a family history of addiction responded even better to the opioid blocker, which has been shown in other studies to decrease the urge to use substances such as alcohol. Grant also found that family history plays an important role in refining this group even further. In the first subtype, gamblers who are driven by urge responded well to treatment with medications that block the brain opioid system (e.g., naltrexone) or certain receptors for the neurotransmitter glutamate (e.g., memantine). In order to group individuals into categories that address differences in their biology, Grant separated pathological gamblers into two major subtypes: gamblers who are driven by urge (i.e., individuals who report gambling when the desire becomes too strong to control), and those who do not show normal inhibition of impulsive behaviors (i.e., individuals who report being unable to restrict behaviors even when urges are minimal or virtually non-existent). Researchers sought to understand how gamblers decide whether or not to bet by focusing on two brain processes: urge and inhibition. Study sites varied in size from 70 to 100 participants. They enrolled men and women with a primary diagnosis of pathological gambling in one of three medication studies. Jon Grant and his team at the University of Minnesota used tasks that measure cognition to identify what motivates this extreme type of gambling behavior. People with pathological gambling disorder will continue their gambling behavior in the face of damaging consequences to themselves and their families.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |